Rho-kinase inhibitor targeting the liver prevents liver fibrosis without major systemic adversity in rats
| Project/Area Number |
26861078
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 肝線維化 / 星細胞 / リポソーム / DDS / Rhoキナーゼ阻害剤 / 肝星細胞 / Drug Delivery System |
|---|
| Outline of Final Research Achievements |
Rho-kinase (ROCK) inhibitors improve liver blood flow after ischemia/reperfusion (IR) injury or improve liver fibrosis, by preventing the activation of hepatic stellate cell (HSC). However, the systemic administration of ROCK inhibitors causes severe hypotension; therefore, liver-specific ROCK inhibition is required. Here, we tested vitamin A coupled liposomes carrying the ROCK inhibitor for targeted HSCs in rat IR model and liver fibrosis model. Liposomal ROCK inhibitor was 100-fold more effective in inhibiting HSC activation than free ROCK inhibitor without major systemic adversity in rats.
|
Report
(3 results)
Research Products
(3 results)
